A detailed history of Black Rock Inc. transactions in I Mab stock. As of the latest transaction made, Black Rock Inc. holds 7,684 shares of IMAB stock, worth $6,915. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,684
Previous 7,923 3.02%
Holding current value
$6,915
Previous $14,000 14.29%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$1.58 - $1.9 $377 - $454
-239 Reduced 3.02%
7,684 $12,000
Q1 2024

May 10, 2024

SELL
$1.54 - $2.37 $141,898 - $218,376
-92,142 Reduced 92.08%
7,923 $14,000
Q4 2023

Feb 13, 2024

SELL
$1.21 - $1.9 $754,090 - $1.18 Million
-623,215 Reduced 86.17%
100,065 $190,000
Q3 2023

Nov 13, 2023

SELL
$1.18 - $3.06 $1.58 Million - $4.09 Million
-1,335,361 Reduced 64.87%
723,280 $954,000
Q2 2023

Aug 11, 2023

BUY
$2.95 - $3.85 $330,370 - $431,161
111,990 Added 5.75%
2,058,641 $6.16 Million
Q1 2023

May 12, 2023

SELL
$3.08 - $7.39 $134,913 - $323,704
-43,803 Reduced 2.2%
1,946,651 $6.74 Million
Q4 2022

Feb 13, 2023

SELL
$3.22 - $4.86 $905,518 - $1.37 Million
-281,217 Reduced 12.38%
1,990,454 $8.32 Million
Q3 2022

Nov 14, 2022

SELL
$4.01 - $12.34 $1.47 Million - $4.52 Million
-366,161 Reduced 13.88%
2,271,671 $9.11 Million
Q2 2022

Aug 12, 2022

SELL
$8.27 - $18.43 $6.33 Million - $14.1 Million
-765,439 Reduced 22.49%
2,637,832 $29.8 Million
Q1 2022

May 12, 2022

BUY
$12.54 - $46.93 $11.8 Million - $44 Million
938,531 Added 38.08%
3,403,271 $55.3 Million
Q4 2021

Feb 10, 2022

BUY
$45.28 - $74.5 $25.9 Million - $42.6 Million
572,142 Added 30.23%
2,464,740 $117 Million
Q3 2021

Nov 09, 2021

BUY
$57.18 - $84.43 $5.76 Million - $8.5 Million
100,726 Added 5.62%
1,892,598 $137 Million
Q2 2021

Aug 11, 2021

BUY
$47.86 - $83.95 $85.8 Million - $150 Million
1,791,872 New
1,791,872 $150 Million

Others Institutions Holding IMAB

About I-Mab


  • Ticker IMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,098,800
  • Market Cap $74.8M
  • Description
  • I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...
More about IMAB
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.